LSE - Delayed Quote GBp
Celadon Pharmaceuticals Plc (CEL.L)
4.5000
0.0000
(0.00%)
At close: May 2 at 11:30:29 AM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
75
75
24
2
--
Cost of Revenue
--
--
90
12
--
Gross Profit
75
75
-66
-10
--
Operating Expense
6,291
6,291
12,851
2,703
720.6470
Operating Income
-6,216
-6,216
-12,917
-2,713
-720.6470
Net Non Operating Interest Income Expense
-566
-566
-4,028
-646
-339.1460
Pretax Income
-7,523
-7,523
-18,118
-4,796
-1,059.7930
Tax Provision
-261
-261
-707
-13
--
Net Income Common Stockholders
-7,140
-7,140
-17,006
-4,628
-1,059.7930
Diluted NI Available to Com Stockholders
-7,140
-7,140
-17,006
-4,628
-1,059.7930
Basic EPS
-0.12
--
-0.30
-0.58
-0.02
Diluted EPS
-0.12
--
-0.30
-0.58
-0.02
Basic Average Shares
61,893.9060
--
57,295.0860
8,033.4090
61,669.7730
Diluted Average Shares
61,893.9060
--
57,295.0860
8,033.4090
61,669.7730
Total Operating Income as Reported
-5,931
-5,931
-5,381
-2,713
-720.6470
Rent Expense Supplemental
--
--
--
--
87.5790
Total Expenses
6,291
6,291
12,941
2,715
720.6470
Net Income from Continuing & Discontinued Operation
-7,140
-7,140
-17,006
-4,628
-1,059.7930
Normalized Income
-6,424.7080
-6,424.7080
-15,878.7728
-3,194.8951
-1,059.7930
Interest Income
32
32
12
--
0.0060
Interest Expense
598
598
4,040
646
339.1520
Net Interest Income
-566
-566
-4,028
-646
-339.1460
EBIT
-6,925
-6,925
-14,078
-4,150
-720.6410
EBITDA
-6,391
-6,391
-13,612
-3,831
-559.7930
Reconciled Cost of Revenue
--
--
90
12
--
Reconciled Depreciation
534
534
466
319
160.8480
Net Income from Continuing Operation Net Minority Interest
-7,140
-7,140
-17,006
-4,628
-1,059.7930
Total Unusual Items Excluding Goodwill
-741
-741
-1,173
-1,437
--
Total Unusual Items
-741
-741
-1,173
-1,437
--
Normalized EBITDA
-5,650
-5,650
-12,439
-2,394
-559.7930
Tax Rate for Calcs
0
0
0
0
--
Tax Effect of Unusual Items
-25.7080
-25.7080
-45.7728
-3.8951
--
12/31/2020 - 3/31/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade